Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 1.6% after the company's loss against Amgen (NASDAQ:AMGN) in a patent case over Regeneron's blockbuster Eylea drug was affirmed by an appeals court.

The long-running legal dispute between Amgen and Sanofi/Regeneron on two key patents covering the use of PCSK9 inhibitors to lower cholesterol has come to an end, with Sanofi emerging as the victor.

11:09 EDT Regeneron (REGN) down 3% after appeals court decision in Amgen (AMGN) patent fight Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed ...

On October 1, 2024, the district court denied Regeneron’s motion for a preliminary injunction against Amgen on the grounds that Regeneron had failed to establish a likelihood of success in ...

An appeals court has upheld a District Court’s denial of a preliminary injunction for Amgen’s (AMGN ... but somewhat expected” for Regeneron (REGN). While extended timelines for an ...

The RAINIER Study (NCT06496607) is an ongoing Phase IIa clinical trial investigating Solrikitug for adults with asthma. This randomized, double-blind, placebo-controlled study evaluates three dose ...

Amgen’s management commented that in the last nine weeks of 2024 alone, Pavblu generated $31 million in sales. That’s fantastic for a brand-new drug. Should Regeneron wish to compete ...

South Korea’s pharmaceutical giant Celltrion said Thursday it has received regulatory approvals for three biosimilars in ...

After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma ...

Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.